Interní Med. 2016; 18(2): 61-65 | DOI: 10.36290/int.2016.015

Idiopathic pulmonary fibrosis - or what new in idiopathic interstitial pneumonia

MUDr.Martina Doubková
Klinika nemocí plicních a tuberkulózy LF Masarykovy univerzity a FN Brno, pracoviště Bohunice

Interstitial lung diseases, also called difuse parenchymal lung disorders, are characterized by a variable degree of inflammatory

and fibrotic changes affecting interstitial spaces, air spaces and alveolar walls. New knowledge about these diseases led in 2013

to create a new classification of one of the subgroups of interstitial lung diseases called idiopathic interstitial pneumonias (IIPs).

IIPs are divided into major, rare and unclassifiable. Major IIPs are subdivided into chronic IIPs, smoking-related IIPs and acute/

subacute IIPs. Idiopathic pulmonary fibrosis (IPF), the most common and severe form IIP, with a poor prognosis. IPF is characterised

by progressive respiratory failure resulting from a relentless fibrosis leading to destruction of the lung architecture. Knowledge

of the disease, along with the possibility of new treatment modalities increases the likelihood of early diagnosis, affecting the

course of the disease and improves quality of life.

Keywords: interstitial lung diseases, classification, idiopathic interstitial pneumonia, idiopathic pulmonary fibrosi

Published: May 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Doubková M. Idiopathic pulmonary fibrosis - or what new in idiopathic interstitial pneumonia. Interní Med. 2016;18(2):61-65. doi: 10.36290/int.2016.015.
Download citation

References

  1. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165(2): 277-304. Go to original source...
  2. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183(6): 788-824. Go to original source...
  3. Raghu G, et al. An official ATS/ERS/JRS/ALT Clinical Practice guideline: Treatment of Idiopathic Pulmonary fibrosis: Executive Summary. An update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 2015; 192(2): 238-248. Go to original source...
  4. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188(6): 733-748. Go to original source...
  5. Vašáková M, Šterclová M. Idiopatická plicní fibróza - doporučený postup pro diagnózu, postup a sledování. http://www.pneumologie.cz/guidelines/. Navštíveno dne 30. 11. 2015.
  6. Doubková M, Skřičková J. Idiopatická plicní fibróza. Vnitr Lek 2005; 51(12): 1375-1384. Go to PubMed...
  7. Vašáková M. Léčba idiopatické plicní fibrózy v České republice v roce 2015. Interní Med. 2015; 17(3): 128-132.
  8. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377(9779): 1760-1769. Go to original source...
  9. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22): 2083-2092. Go to original source... Go to PubMed...
  10. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22): 2071-2082. Go to original source...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.